US 11,913,074 B2
Methods for assessing risk of developing a viral disease using a genetic test
Eli Hatchwell, Winchester (GB); Peggy S. Eis, Fitchburg, WI (US); Edward B. Smith, III, New York, NY (US); and Yassine Taoufik, Paris (FR)
Assigned to PML Screening, LLC, Newport Beach, CA (US); The Université Paris-Saclay, Saint Aubin (FR); The Assistance Publique—Hôpitaux de Paris (APHP), Paris (FR); and The Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR)
Filed by PML Screening, LLC, Newport Beach, CA (US); The Université Paris-Saclay, Saint Aubin (FR); The Assistance Publique—Hôpitaux de Paris (APHP), Paris (FR); and The Institut National de la Santé et de la Recherche Médicale (INSERM), Paris (FR)
Filed on Mar. 17, 2023, as Appl. No. 18/185,898.
Application 18/185,898 is a division of application No. 17/161,171, filed on Jan. 28, 2021.
Application 17/161,171 is a division of application No. 16/602,348, filed on Aug. 15, 2019, granted, now 10,961,585, issued on Mar. 30, 2021.
Application 16/602,348 is a continuation of application No. PCT/US2019/045721, filed on Aug. 8, 2019.
Claims priority of provisional application 62/716,183, filed on Aug. 8, 2018.
Claims priority of provisional application 62/716,072, filed on Aug. 8, 2018.
Prior Publication US 2023/0265520 A1, Aug. 24, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/68 (2018.01); C12Q 1/6883 (2018.01)
CPC C12Q 1/6883 (2013.01) [C12Q 2600/106 (2013.01); C12Q 2600/156 (2013.01)] 24 Claims
 
1. A method of treating a condition in a subject in need of immunosuppressive therapy comprising: administering a therapeutically effective amount of an immunosuppressive agent to the subject, wherein the subject has a decreased risk of progressive multifocal leukoencephalopathy (PML) due to an infection of the brain by John Cunningham virus (JCV), wherein the subject's decreased risk is associated with the absence of one or more genetic variations in the subject, wherein the subject has been tested for a presence of the one or more genetic variations with a genetic assay and has been identified as not having the one or more genetic variations;
wherein the one or more genetic variations disrupts or modulates a C8B gene, a FCN2 gene, or a LY9 gene.